Related Experiment Video
Updated: Mar 12, 2026
06:08
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
2.4K
Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors
Rong-Liang Shi1,2, Ning Qu1, Ting-Xian Luo1
11 Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University , Shanghai, China .
Thyroid : Official Journal of the American Thyroid Association
|November 10, 2016
Summary
Programmed death-ligand 1 (PD-L1) expression is common in papillary thyroid cancer (PTC) and linked to aggressive features. High PD-L1 expression predicts a worse recurrence-free survival, suggesting it as a treatment target.
Area of Science:
- Oncology
- Immunology
- Pathology
Background:
- Programmed death-ligand 1 (PD-L1) expression is observed in various cancers.
- PD-L1 expression in papillary thyroid cancer (PTC) is infrequently characterized.
- This study investigates PD-L1's role in PTC aggressiveness and patient outcomes.
Purpose of the Study:
- To assess PD-L1 expression in PTC.
- To correlate PD-L1 expression with clinicopathologic factors.
- To determine the prognostic significance of PD-L1 in PTC recurrence-free survival (RFS).
Main Methods:
- Retrospective immunohistochemistry analysis of PD-L1 in 260 PTC tumors and adjacent non-tumor tissues.
- Correlation analysis between PD-L1 expression and clinicopathologic features.
- Multivariate Cox regression and subgroup analyses to evaluate RFS.
Main Results:
- PD-L1 was expressed in 52.3% of PTC tumors, significantly higher than in non-tumor tissues.
- Positive PD-L1 staining correlated with multifocality and extrathyroidal extension.
- PD-L1 expression was an independent predictor of worse RFS (HR 2.825, p=0.024).
- Worse RFS associated with PD-L1 was observed in males, older patients, larger tumors, multifocal disease, extrathyroidal extension, and lymph node metastasis.
- PD-L1 predicted worse RFS in patients without Hashimoto's thyroiditis and those treated with total thyroidectomy.
Conclusions:
- PD-L1 expression is a significant factor in PTC aggressiveness.
- PD-L1 can predict patient prognosis and recurrence risk.
- Targeting PD-L1 may offer a therapeutic strategy for advanced PTC with high PD-L1 expression.
